Omalizumab in patients with severe asthma: the XCLUSIVE study
The Clinical Respiratory Journal, 04/17/2012Schumann C et al.
Results of effectiveness strongly suggest that the efficacy demonstrated in randomised controlled trials (RCTs) can be transposed to a clinical practice–related setting.
One hundred ninety–five asthmatic patients initiated on anti–Immunoglobulin E (IgE) IgE treatment were followed–up for 6 months.
Forced expiratory volume in 1 s (FEV1), exacerbation rate, days of absence, asthma symptoms [Asthma Control Questionnaire (ACQ)], a Global Evaluation of Treatment Effectiveness (GETE) and medication use were assessed.
Measured outcome variables improved after a 16–week treatment period with OMA (FEV1+13.7% predicted P < 0.05, exacerbation rate –74.9% P < 0.0001, days of absence –92.1% P < 0.001, ACQ -43.7% P < 0.0001).
Investigators evaluated the effectiveness of OMA by GETE in 78.8% as excellent or good (responder), and in 12.6%/8.6% as moderate/poor or worse (non–responder).
Responders demonstrated better improvement of FEV1, exacerbation rate, days of absence, ACQ and reduction of oral corticosteroids compared with non–responders.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.